The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Ebina, Kosuke; Miyama, Akira; Tsuboi, Hideki; Kaneshiro, Shoichi; Nishikawa, Masataka; Owaki, Hajime; Tsuji, Shigeyoshi; Hirao, Makoto; Etani, Yuki; Goshima, Atsushi; Hashimoto, Jun; Yoshikawa, Hideki

doi:https://doi.org/10.1080/14397595.2018.1486939

The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Ebina, Kosuke; Miyama, Akira; Tsuboi, Hideki et al.

Modern Rheumatology, 2019, 29(4), 581-588

アクセス数:1,250件（2025-07-17 14:22 集計）

固定URL: https://hdl.handle.net/11094/93253

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ModRheumatol_29_4_581	pdf	なし	0.99 MB	107	2023.12.07

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	著者名 Miyama, Akira
	著者名 Tsuboi, Hideki
	著者名 Kaneshiro, Shoichi
	著者名 Nishikawa, Masataka
	著者名 Owaki, Hajime
	著者名 Tsuji, Shigeyoshi
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	NRID 1000060898930 1000060898930 著者名 Etani, Yuki
	著者名 Goshima, Atsushi
	NRID 1000040237938 1000040237938 著者名 Hashimoto, Jun
	NRID 1000060191558 1000060191558 著者名 Yoshikawa, Hideki
キーワード等	Iguratimod
	inadequate response
	rheumatoid arthritis
	tocilizumab
内容	Ebina K., Miyama A., Tsuboi H., et al. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Modern Rheumatology 29, 581 (2019); https://doi.org/10.1080/14397595.2018.1486939.
抄録	Objectives: To evaluate the effectiveness of add-on iguratimod (IGU) in patients with rheumatoid arthritis (RA) who showed an inadequate response to tocilizumab (TCZ), especially patients who were intolerant of an effective dose of methotrexate (MTX). Methods: Thirty-one patients with RA (22 women, age 62.4 years, disease duration 13.8 years, prior TCZ duration 35.7 months, 25 intravenous [8 mg/kg/4 weeks] and 6 subcutaneous [162 mg/2 weeks] TCZ treatments, concomitant MTX 8.5 mg/week [35.5%], and prednisolone (PSL) 4.3 mg/day [25.8%]) who showed an inadequate response to TCZ (disease activity score assessing 28 joints with C-reactive protein [DAS28-CRP] 2.9, clinical disease activity index [CDAI] 15.0, 28 secondary inadequate responders) were treated with additional IGU (final dose 41.7 mg/day) and enrolled in this 24-week, multicenter, retrospective study. Results: Twenty-nine patients (93.5%) continued the treatment for 24 weeks (one dropped out for pneumonia and one for digestive symptoms). The TCZ and the concomitant dose and rate of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (MTX, salazosulfapyridine [SASP], and tacrolimus [TAC]) were not significantly changed during this period. Outcome measures improved significantly, as follows: DAS28-CRP from 2.9 to 1.7 (p <.001); CDAI from 15.0 to 6.0 (p <.001); modified Health Assessment Questionnaire (mHAQ) from 0.8 to 0.6 (p <.05); and rheumatoid factor (RF) from 382.1 to 240.3 IU/mL (p <.001). Using the EULAR criteria, 64.5% achieved a moderate response, and 51.6% achieved ACR 20 at 24 weeks. Conclusion: Adding IGU to inadequate responders to TCZ may be a promising and safe complementary treatment option.
出版者	Taylor and Francis Ltd
収録物名	Modern Rheumatology
巻(号)	29(4)
ページ	581-588
刊行年月	2019-07-04
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93253
PISSN	14397595
eISSN	14397609
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1080/14397595.2018.1486939
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Modern Rheumatology. 2019, 29(4), p. 581-588
DC.title	The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
DC.creator	Ebina, Kosuke
	Miyama, Akira
	Tsuboi, Hideki
	Kaneshiro, Shoichi
	Nishikawa, Masataka
	Owaki, Hajime
	Tsuji, Shigeyoshi
	Hirao, Makoto
	Etani, Yuki
	Goshima, Atsushi
	Hashimoto, Jun
	Yoshikawa, Hideki
DC.publisher	Taylor and Francis Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2019-07-04
DC.identifier	https://doi.org/10.1080/14397595.2018.1486939
DC.subject	Iguratimod
	inadequate response
	rheumatoid arthritis
	tocilizumab
DC.description	Ebina K., Miyama A., Tsuboi H., et al. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Modern Rheumatology 29, 581 (2019); https://doi.org/10.1080/14397595.2018.1486939.
DCTERMS.abstract	Objectives: To evaluate the effectiveness of add-on iguratimod (IGU) in patients with rheumatoid arthritis (RA) who showed an inadequate response to tocilizumab (TCZ), especially patients who were intolerant of an effective dose of methotrexate (MTX). Methods: Thirty-one patients with RA (22 women, age 62.4 years, disease duration 13.8 years, prior TCZ duration 35.7 months, 25 intravenous [8 mg/kg/4 weeks] and 6 subcutaneous [162 mg/2 weeks] TCZ treatments, concomitant MTX 8.5 mg/week [35.5%], and prednisolone (PSL) 4.3 mg/day [25.8%]) who showed an inadequate response to TCZ (disease activity score assessing 28 joints with C-reactive protein [DAS28-CRP] 2.9, clinical disease activity index [CDAI] 15.0, 28 secondary inadequate responders) were treated with additional IGU (final dose 41.7 mg/day) and enrolled in this 24-week, multicenter, retrospective study. Results: Twenty-nine patients (93.5%) continued the treatment for 24 weeks (one dropped out for pneumonia and one for digestive symptoms). The TCZ and the concomitant dose and rate of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (MTX, salazosulfapyridine [SASP], and tacrolimus [TAC]) were not significantly changed during this period. Outcome measures improved significantly, as follows: DAS28-CRP from 2.9 to 1.7 (p <.001); CDAI from 15.0 to 6.0 (p <.001); modified Health Assessment Questionnaire (mHAQ) from 0.8 to 0.6 (p <.05); and rheumatoid factor (RF) from 382.1 to 240.3 IU/mL (p <.001). Using the EULAR criteria, 64.5% achieved a moderate response, and 51.6% achieved ACR 20 at 24 weeks. Conclusion: Adding IGU to inadequate responders to TCZ may be a promising and safe complementary treatment option.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	93253
citation_title	The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
citation_author	Ebina, Kosuke
	Miyama, Akira
	Tsuboi, Hideki
	Kaneshiro, Shoichi
	Nishikawa, Masataka
	Owaki, Hajime
	Tsuji, Shigeyoshi
	Hirao, Makoto
	Etani, Yuki
	Goshima, Atsushi
	Hashimoto, Jun
	Yoshikawa, Hideki
citation_publisher	Taylor and Francis Ltd
citation_language	英語
citation_date	2019-07-04
citation_journal_title	Modern Rheumatology
citation_volume	29
citation_issue	4
citation_firstpage	581
citation_lastpage	588
citation_doi	https://doi.org/10.1080/14397595.2018.1486939
citation_public_url	https://hdl.handle.net/11094/93253

The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

閲覧可能ファイル

論文情報

論文詳細を表示